Sage Therapeutics - SAGE EV/Sales Multiple

Sage Therapeutics, Inc. (SAGE) is a recognized expert in neuromedicine dedicated to returning patients to a full life. The company is focused on the market launch of its unique oral medication, Zurzuvae. Asset value growth is supported by a partnership with Biogen and the expansion of insurance coverage. The company's EV-to-revenue ratio visualizes market expectations, where reflects the baseline metric level, adjusted for the impact of debt load.
Financial and market metric breakdowns for Sage Therapeutics (SAGE)

Investors must determine the fair value of the asset by analyzing the enterprise value to revenue ratio. Evaluating Sage Therapeutics, Inc. (SAGE) via EV/Sales allows for the identification of whether the business is overvalued or undervalued, which is critical for Sage Therapeutics, Inc. (SAGE), as its financial stability currently depends entirely on the commercial success of a single drug within a narrow neurological segment.